417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

Leora Horn(Vanderbilt University), Julie R. Brahmer(Johns Hopkins Hospital), Martin Reck(LungenClinic Grosshansdorf), Hossein Borghaei(Fox Chase Cancer Center), David R. Spigel(Sarah Cannon), Martin Steins, Neal Ready(Duke Medical Center), Laura Q.M. Chow(Seattle Cancer Care Alliance), Everett E. Vokes(University of Chicago Medical Center), Enriqueta Felip(Vall d'Hebron Hospital Universitari), Esther Holgado(Hospital Universitario HM Sanchinarro), Fabrice Barlési(Hôpital Nord), Martin Kohlhäufl(Klinik Schillerhöhe), Marco Angelo Burgio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Jérôme Fayette(Centre Léon Bérard), Scott Gettinger(Yale University), Christopher Harbison(Bristol-Myers Squibb (United States)), A. Li(Bristol-Myers Squibb (United States)), F. Graf Finckenstein(Bristol-Myers Squibb (United States)), Luis Paz‐Ares(Hospital Universitario Virgen del Rocío)
Annals of Oncology
December 1, 2015
10.1093/annonc/mdv532.01
Cited by 13Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis